Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Weibimei plus triple therapy for H. pylori–positive chronic gastritis
ChiCTR2000040054Phase 4Not yet recruiting
- Sponsor
- Peking University First Hospital
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of compound bismuth aluminate in chronic gastritis and Helicobacter pylori infection (3 arms), sponsored by Peking University First Hospital. Primary endpoint: H. pylori eradication rate. Planned start Nov 2020; status: not yet recruiting.
02
Drugs
compound bismuth aluminate
03
Conditions
chronic gastritisHelicobacter pylori infection
Beyond the preview
Go deeper on ChiCTR2000040054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000040054.